祝賀上海信帆生物供應(yīng)的ELISA試劑盒榮登《Clinical 》
更新時(shí)間：2019-09-05 點(diǎn)擊次數(shù)：1059次祝賀上海信帆生物供應(yīng)的ELISA試劑盒榮登《Clinical Rheumatology》
祝賀我司客戶的研究成果被期刊《Clinical Rheumatology》收錄
該論文標(biāo)題： Predictors of response to TNFα antagonist therapy in Chinese rheumatoid arthritis
Clinical Rheumatology
發(fā)表日期：July 2015, Volume 34
期刊號：Issue 7, pp 1203–1210
老師在論文后期編輯過程中與我們積極互動(dòng)，信帆生物給予了支持，終順利被《Clinical Rheumatology》錄用。
以下是老師論文中使用我司產(chǎn)品的截圖
該論文中所使用的以下ELISA試劑盒均購自我司。
Human IL-34 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human TNF-a ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human IL-6 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human IL-8 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
Human MMP-3 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)
信帆生物是一家專業(yè)的elisa試劑盒供應(yīng)商,銷售各種進(jìn)口國產(chǎn)品牌的elisa試劑盒。
對于elisa試劑盒,我們提供完善的質(zhì)量保證,專業(yè)的技術(shù)解答,耐心周到的售后服務(wù),成為國內(nèi)多家科研機(jī)構(gòu)和高校的試劑盒供應(yīng)商。
信帆生物從創(chuàng)立至今，具有多年試劑領(lǐng)域的研發(fā)、生物試劑和銷售經(jīng)驗(yàn)，目前已經(jīng)成長為國內(nèi)規(guī)模的試劑研發(fā)、生物試劑和銷售的綜合性企業(yè)，一直為科研工作者助力。我們期待您的光臨！
熱烈祝賀上海信帆客戶又一篇SCI文章被期刊收錄
《Clinical Rheumatology》期刊介紹：
Clinical Rheumatology is an international journal devoted to publishing in the English language original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level. Studies carried out anywhere in the world will be considered the basic criterion for acceptance being the medical and scientific standard of the work described.
文章介紹
This study aimed to investigate the clinical, immunological, and radiologic predictors of response to tumor necrosis factor (TNF)-α antagonist therapy in Chinese rheumatoid arthritis (RA). Ninety RA patients were divided into two groups according to their responsiveness to TNF-α antagonist therapy at 1 month: group A (responders) and group B (non-responders). After 3 months of therapy, all the 90 patients were re-assessed and re-divided into another two groups: group C (responders) and group D (non-responders). Serum samples and clinical characteristics as well as radiographic features were collected at baseline, first month, and third month post-initial administration of TNF-α antagonist. Serum TNF-α, interleukin (IL)-6, IL-8, IL-34, and matrix metalloproteinase (MMP)-3 were measured by enzyme-linked immunosorbent assay (ELISA). Disease activity and Sharp score were evaluated. (1) Comparisons between groups A and B: subjects in group A showed a lower level of erythrocyte sedimentation rate (ESR) and a higher level of albumin (ALB) at baseline than that of group B (p < 0.05). The cutoff value of ALB for prediction was ≥34.9 g/l and that of ESR was ≤55.5 mm/h. (2) Comparisons between groups C and D: group C showed lower levels of ESR, health assessment questionnaire (HAQ), and IL-34 at baseline (p < 0.05). The threshold for prediction were as follows: ESR ≤60 mm/h, HAQ ≤1.3125, and IL-34 ≤194.12 pg/ml. (3) The serum cytokines were positively correlated with C-reactive protein (CRP) and disease activity index, while ALB was negatively correlated with CRP and disease activity. Baseline ALB ≥34.9 g/l or ESR ≤55.5 mm/h might predict a good response at 1-month treatment of TNF-α antagonist, while baseline ESR ≤60 mm/h, HAQ ≤1.3125, and IL-34 ≤194.12 pg/ml might predict a good response at 3-month treatment.
祝賀上海信帆生物供應(yīng)的ELISA試劑盒榮登《Clinical Rheumatology》
